Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02333188
Other study ID # IRB14-0595
Secondary ID NCI-2014-02407IR
Status Completed
Phase Phase 1
First received
Last updated
Start date December 2014
Est. completion date December 2017

Study information

Verified date May 2023
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects of genetic analysis-guided dosing of paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRABRAX) in treating patients with gastrointestinal cancer that has spread to other parts of the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.


Description:

PRIMARY OBJECTIVES: I. To determine the dose-limiting toxicity (DLT) rate in cycle #1 in each of three uridine diphosphate (UDP) glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotype groups (*1/*1, *1/*28, *28/*28) using genotype-guided dosing of irinotecan (irinotecan hydrochloride) as part of the FOLFIRABRAX regimen. SECONDARY OBJECTIVES: I. To determine the cumulative dose of each chemotherapy drug (nab-paclitaxel [paclitaxel albumin-stabilized nanoparticle formulation], irinotecan, 5-FU [fluorouracil]) administered in each genotype group. II. To determine the response rates (in patients with measurable disease) by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) for each different disease (pancreatic cancer, biliary tract cancer, esophageal/gastric cancer, adenocarcinoma of unknown primary) treated in the study. OUTLINE: Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that FOLFIRABRAX is a reasonable therapeutic option - Patients with a history of obstructive jaundice due to the primary tumor must have a metal biliary stent in place - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 - Life expectancy > 3 months - Absolute neutrophil count (ANC) >= 1500/ul - Hemoglobin > 9 g/dL - Platelets > 100,000/ul - Total bilirubin =< 1.25 times upper limit of normal - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal - Alkaline phosphatase =< 2.5 times the upper limit of normal, unless bone metastasis is present in the absence of liver metastasis - Creatinine =< 1.5 mg/dL - Measurable or non-measurable disease will be allowed, but only those with measurable disease will be evaluable for the response rate endpoint - Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment - Negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential - Signed informed consent Exclusion Criteria: - Prior chemotherapy or radiation therapy for any cancer - Inflammatory bowel disease (Crohn's disease, ulcerative colitis) - Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v.] 4.0); pancreatic cancer patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement - Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0 - Documented brain metastases - Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment - Active uncontrolled bleeding - Pregnancy or breastfeeding - Major surgery within 4 weeks - Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30% - Patients taking substrates, inhibitors and inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible - Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g., *6) - History of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis or connective tissue disorders - Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Adenocarcinoma of Unknown Primary
  • Adult Cholangiocarcinoma
  • Cholangiocarcinoma
  • Digestive System Neoplasms
  • Gallbladder Carcinoma
  • Gallbladder Neoplasms
  • Gastric Adenocarcinoma
  • Gastrointestinal Neoplasms
  • Malignant Gastrointestinal Neoplasm
  • Metastatic Pancreatic Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Pancreatic Neoplasms
  • Stage III Ampulla of Vater Cancer
  • Stage III Pancreatic Cancer
  • Stage IIIA Gallbladder Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIB Gallbladder Cancer
  • Stage IIIB Gastric Cancer
  • Stage IV Ampulla of Vater Cancer
  • Stage IV Gallbladder Cancer
  • Stage IV Gastric Cancer
  • Stage IV Pancreatic Cancer
  • Stomach Neoplasms

Intervention

Drug:
Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Given IV
Leucovorin Calcium
Given IV
Irinotecan Hydrochloride
Given IV
Fluorouracil
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies

Locations

Country Name City State
United States The University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States University of Chicago Comprehensive Cancer Center Chicago Illinois
United States Decatur Memorial Hospital Decatur Illinois
United States NorthShore University Health System Evanston Illinois
United States Fort Wayne Medical Oncology/Hematology Fort Wayne Indiana
United States Ingalls Memorial Hospital Harvey Illinois
United States Indiana University Medical Center Indianapolis Indiana
United States Virginia Mason Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Chicago National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLT rate in course 1 for each of the three genotype groups, graded according to NCI CTCAE v 4.0 4 weeks
Secondary Incidence of adverse events graded according to NCI CTCAE v 4.0 Adverse events will be summarized by type, grade, and attribution. Up to 6 months
Secondary Response rates (by RECIST 1.1) for patients with each different type of gastrointestinal malignancy These results will be compared descriptively to appropriate historical controls. Exact 90% confidence intervals will be generated for the response rates. Up to 6 months
Secondary Cumulative doses of the drugs will be calculated as the sum of all doses received on protocol therapy for each patient The means and standard deviations for patients in each genotype group will be reported. Up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed NCT01959672 - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03673423 - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Not yet recruiting NCT06026943 - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer N/A
Completed NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02072616 - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Phase 3
Completed NCT02174887 - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Phase 1
Recruiting NCT03703063 - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer Phase 1
Terminated NCT04077372 - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers N/A
Recruiting NCT03073785 - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer Phase 2
Completed NCT03665441 - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Phase 3
Recruiting NCT04627246 - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer Phase 1
Not yet recruiting NCT06217666 - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) Phase 1
Recruiting NCT05585320 - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04119362 - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed NCT03105921 - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma N/A